Ischemic Stroke with Recovery of Essential Hypertension (Grade 1)
Conditions
Interventions
test group:Getong Tongluo capsules
Ginkgo biloba extract tablet simulator
Positive control drug group:Ginkgo biloba extract tablets
Getong Tongluo Capsules Simulator
placebo group:Getong Tongluo Capsules Simulator, Ginkgo biloba extract tablet simulator
Sponsors
Dongfang Hospital of Beijing University of Chinese Medicine; Xiangya Hospital Central, South University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who accord with Western diagnostic criteria for ischemic stroke (anterior circulation patients ); 2. Patients with primary hypertension (Grade 1) Western medicine diagnostic criteria; 3. Patients with the diagnosis of traditional Chinese medicine blood stasis syndrome; 4. Patients with onset time within 2 weeks and within 3 months; 5. NIHSS score = 6 and = 22; 6, aged 18-75 years old; 7. Patients with first-episode or recurrent stroke have completely recovered their patients before the onset of the disease, and their mRS score is 0-1; 8. Those who signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. A history of intracerebral hemorrhage (including subarachnoid hemorrhage) in the past half years; 2. Patients with clinically-derived cardiac infarction and other definite and unexplained types; 3. It has been confirmed by examination that cerebral infarction, brain trauma, cerebral parasitosis, metabolic disorders, rheumatic heart disease, coronary heart disease, and other heart diseases have cerebral thrombosis caused by thrombosis of atrial fibrillation associated with atrial fibrillation.; 4. Incorporate other functional disorders that affect physical activity, such as combined lameness, osteoarthritis (active phase), rheumatoid arthritis (active phase), gouty arthritis, and other limb activity dysfunction may affect neurological or functional testers; 5.Patients with diabetic complications (eg, severe diabetic nephropathy leading to renal insufficiency, diabetic peripheral neuropathy affecting motor function assessor, diabetic ketoacidosis, etc.) and patients with recurrent hypoglycemia; 6. Patients with severe malnutrition and severe hematological diseases (such as hypoalbuminemia, severe anemia, etc.) and serious electrolyte disturbances cannot be corrected after treatment; 7. Patients with severe heart and lung system diseases and chronic liver and kidney dysfunction, among which liver function damage ALT, AST > 1.2 times the upper limit of normal, renal function creatinine (Cr)> normal upper limit; 8, pregnant or lactating women; 9. Patients with disabilities prescribed by law (blind, deaf, dumb, intellectual disabilities, mental disorders, physical disabilities); 10. Known to allergies and allergies to the drug ingredients; 11. The researcher believes that there are any patients who are not suitable for inclusion or influence the factors that participate in or complete the study; 12. Patients who participated in other clinical trials within 12 or 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRS;MRS;BI; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS;SBP;DBP;Rate of BP;Incidence of cardiovascular and cerebrovascular events (stroke, myocardial infarction, TIA, cerebral hemorrhage, death, etc.Incidence of cardiovascular and cerebrovascular events (stroke, myocardial infarction, TIA, cerebral hemorrhage, death, etc.;TCM symptom score;Four lipids and glycosylated hemoglobin improvement; | — |
Countries
China
Contacts
Public ContactChen Zhigang;Liu Yunhai
Dongfang Hospital of Beijing University of Chinese Medicine/Xiangya Hospital Central South University
Outcome results
None listed